Cardinal Health (CAH) Shareholder Diam Company LTD Trimmed Stake by $841,302 as Shares Declined; Palo Alto Investors Lowered Its United Therapeutics Del (UTHR) Holding by $12.25 Million; Stock Value Declined

February 15, 2018 - By Linda Rogers

Diam Company Ltd decreased its stake in Cardinal Health Inc (CAH) by 2.48% based on its latest 2017Q3 regulatory filing with the SEC. Diam Company Ltd sold 12,747 shares as the company’s stock declined 8.93% while stock markets rallied. The institutional investor held 500,403 shares of the health care company at the end of 2017Q3, valued at $33.49M, down from 513,150 at the end of the previous reported quarter. Diam Company Ltd who had been investing in Cardinal Health Inc for a number of months, seems to be less bullish one the $21.32B market cap company. The stock increased 0.59% or $0.4 during the last trading session, reaching $67.74. About 706,612 shares traded. Cardinal Health, Inc. (NYSE:CAH) has declined 4.95% since February 15, 2017 and is downtrending. It has underperformed by 21.65% the S&P500.

William Leland Edwards decreased its stake in United Therapeutics Corp Del (UTHR) by 5.61% based on its latest 2017Q3 regulatory filing with the SEC. Palo Alto Investors Llc sold 104,665 shares as the company’s stock declined 27.66% while stock markets rallied. The hedge fund run by William Leland Edwards held 1.76M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $206.57 million, down from 1.87M at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in United Therapeutics Corp Del for a number of months, seems to be less bullish one the $5.84B market cap company. The stock decreased 1.33% or $1.82 during the last trading session, reaching $135.1. About 106,592 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since February 15, 2017 and is uptrending. It has underperformed by 6.92% the S&P500.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics had 28 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, February 23 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The rating was maintained by Argus Research with “Buy” on Friday, July 31. The firm has “Hold” rating by Cowen & Co given on Thursday, July 27. Ladenburg Thalmann upgraded the shares of UTHR in report on Friday, October 28 to “Buy” rating. As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. As per Thursday, October 26, the company rating was maintained by Cowen & Co. The company was initiated on Thursday, December 15 by Oppenheimer. As per Tuesday, July 18, the company rating was maintained by Oppenheimer. On Tuesday, November 29 the stock rating was downgraded by Barclays Capital to “Underweight”. Jefferies maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Sunday, August 13. Jefferies has “Sell” rating and $10500 target.

Palo Alto Investors Llc, which manages about $1.30B and $2.37B US Long portfolio, upped its stake in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 49,400 shares to 1.08M shares, valued at $151.56M in 2017Q3, according to the filing. It also increased its holding in Biomarin Pharmaceutical Inc (NASDAQ:BMRN) by 53,800 shares in the quarter, for a total of 2.44 million shares, and has risen its stake in Insmed Inc (NASDAQ:INSM).

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on February, 28. They expect $3.52 earnings per share, up 33.33% or $0.88 from last year’s $2.64 per share. UTHR’s profit will be $152.11 million for 9.60 P/E if the $3.52 EPS becomes a reality. After $6.27 actual earnings per share reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts -43.86% negative EPS growth.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.04, from 1.03 in 2017Q2. It dropped, as 31 investors sold UTHR shares while 114 reduced holdings. 44 funds opened positions while 100 raised stakes. 41.49 million shares or 6.19% less from 44.22 million shares in 2017Q2 were reported. Aqr Capital Ltd Com stated it has 0.31% in United Therapeutics Corporation (NASDAQ:UTHR). Burney Comm accumulated 119,826 shares. Bank & Trust Of New York Mellon Corporation holds 778,453 shares or 0.03% of its portfolio. Bluemountain Limited holds 0.19% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 77,318 shares. Lsv Asset Mgmt reported 0.03% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Pillar Pacific Mgmt Limited Liability has invested 0.06% in United Therapeutics Corporation (NASDAQ:UTHR). Royal Fincl Bank Of Canada stated it has 0.01% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Evanston Invests Dba Evanston Advsr stated it has 1.59% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Schroder Management Grp holds 0.22% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 1.05 million shares. Invesco Ltd accumulated 351,259 shares. State Board Of Administration Of Florida Retirement holds 77,438 shares or 0.02% of its portfolio. Glg Limited Liability Corporation accumulated 0.02% or 2,063 shares. Robeco Institutional Asset Mgmt Bv reported 158,368 shares stake. Dimensional Fund Ltd Partnership owns 798,093 shares or 0.04% of their US portfolio. Axa holds 0.03% or 66,629 shares.

Since August 17, 2017, it had 0 insider purchases, and 12 selling transactions for $1.70 million activity. $77,998 worth of United Therapeutics Corporation (NASDAQ:UTHR) was sold by CAUSEY CHRISTOPHER.

Among 20 analysts covering Cardinal Health (NYSE:CAH), 4 have Buy rating, 1 Sell and 15 Hold. Therefore 20% are positive. Cardinal Health had 48 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, December 17 by Goldman Sachs. The rating was maintained by Jefferies with “Hold” on Wednesday, June 21. The stock has “Hold” rating by Needham on Tuesday, April 4. The stock of Cardinal Health, Inc. (NYSE:CAH) earned “Conviction Buy” rating by Goldman Sachs on Monday, March 7. RBC Capital Markets maintained it with “Outperform” rating and $95 target in Tuesday, November 3 report. Goldman Sachs downgraded Cardinal Health, Inc. (NYSE:CAH) rating on Friday, September 16. Goldman Sachs has “Neutral” rating and $83 target. On Monday, November 20 the stock rating was downgraded by Morgan Stanley to “Underweight”. The firm earned “Market Perform” rating on Wednesday, January 6 by Raymond James. The stock has “Hold” rating by Robert W. Baird on Wednesday, January 17. Tigress Financial initiated the stock with “Neutral” rating in Friday, April 28 report.

Investors sentiment increased to 0.9 in Q3 2017. Its up 0.03, from 0.87 in 2017Q2. It is positive, as 63 investors sold CAH shares while 229 reduced holdings. 64 funds opened positions while 198 raised stakes. 275.05 million shares or 0.51% more from 273.65 million shares in 2017Q2 were reported. Mufg Americas Holdings accumulated 510 shares or 0% of the stock. Dekabank Deutsche Girozentrale stated it has 434,173 shares or 0.22% of all its holdings. Ameritas Investment Prtn reported 0.05% of its portfolio in Cardinal Health, Inc. (NYSE:CAH). Robeco Institutional Asset Bv reported 0% of its portfolio in Cardinal Health, Inc. (NYSE:CAH). Gam Hldgs Ag, Switzerland-based fund reported 16,040 shares. Chevy Chase Hldg owns 276,145 shares. Regions holds 56,257 shares or 0.04% of its portfolio. Meiji Yasuda Life Insur holds 4,700 shares. Sheets Smith Wealth Mngmt holds 0.62% of its portfolio in Cardinal Health, Inc. (NYSE:CAH) for 36,800 shares. Lpl Fincl Ltd Llc holds 0.01% of its portfolio in Cardinal Health, Inc. (NYSE:CAH) for 33,151 shares. Oppenheimer Asset Mgmt stated it has 14,340 shares or 0.02% of all its holdings. Pnc Fin Services Group owns 120,362 shares for 0.01% of their portfolio. Parkside Bank & Trust has 0% invested in Cardinal Health, Inc. (NYSE:CAH). Motco reported 0% stake. Barrow Hanley Mewhinney & Strauss Ltd Llc owns 20.05 million shares.

Diam Company Ltd, which manages about $42.60B US Long portfolio, upped its stake in Mcgrath Rentcorp (NASDAQ:MGRC) by 23,400 shares to 81,400 shares, valued at $3.58M in 2017Q3, according to the filing. It also increased its holding in Hewlett Packard Enterprise C by 157,160 shares in the quarter, for a total of 3.23 million shares, and has risen its stake in Lyondellbasell Industries N (NYSE:LYB).

Since January 22, 2018, it had 0 insider buys, and 1 sale for $1.37 million activity.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>